Tokyo retreated in the week ended May 18, following a two-week uptrend. The Nikkei 225 dropped 4.4%, to close at the 9,000 mark, while the Topix Index was down 4.5%. Since the market broke through the resistance line of 9,000 the previous week, investors were eager to gain profits. Although players were temporarily encouraged by a report that machinery orders in March showed a smaller-than-anticipated decrease from February, falling only 1.3%, a steep daily setback was registered in the last trading day because of an outbreak of H1N1 swine flu in western Japan that caused worries about a potential negative effect on consumer spending and corporate activities. The pharmaceutical index was down 0.8%, outperforming the market, with the performance of major drug stocks mixed depending on individual company earnings reports.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze